复发难治性弥漫大B细胞淋巴瘤靶向药物治疗进展

淋巴瘤为一组起源于淋巴结或其他淋巴组织的异质性血液系统恶性肿瘤,包括霍奇金淋巴瘤(Hodgkin's lymphoma,HL)和非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL),其中弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)为一类异质性明显的淋巴系统恶性肿瘤,也是最常见的NHL亚型。标准R-CHOP方案(利妥昔单抗联合环磷酰胺、阿霉素、长春新碱和泼尼松)治疗可显著提高60%以上患者的生存期,然而仍有约30%~40%患者出现疾病复发或难治,预后较差,如何延长复发难治性DLBCL患者的生存期并改善其预后已成为目前国内外研究的热点。随着疾病基因表达谱、耐药分子机制等的不断深入研究,化疗新方案及新药不断探索,为个体化精准治疗复发难治性DLBCL带来新希望。本文拟对新近的靶向药物在复发难治性DLBCL中的治疗进展进行综述。

Advances in targeted drug therapy for relapse/refractory diffuse large B-cell lymphoma

Lymphoma is a group of heterogeneous hematological malignant tumors originating from lymph nodes or other lymphoid tissues, including Hodgkin's lymphoma and non-Hodgkin's lymphoma. Diffuse large B-cell lymphoma (DLBCL) is one of the most common subtypes of non-Hodgkin's lymphoma (NHL) with obvious heterogeneity. Standard R-CHOP regimen (rituximab combined with cyclophosphamide, adriamycin, vincristine and prednisone) can significantly improve the survival of more than 60% of patients. However, there are still about 30% - 40% of patients with relapse or refractory disease, and the prognosis is very poor. How to prolong the survival of relapsed/refractory DLBCL patients and improve their prognosis has become a research hotspot. With the continuous in-depth study of gene expression profiles and molecular mechanisms of drug resistance, new chemotherapy schemes and new drugs emerge, which brings new hope for individualized precise treatment of relapsed/refractory DLBCL. This article reviews the recent progress of targeted drugs in the treatment of relapsed/refractory DLBCL.